BioSpace News Archive

Inspira Technologies OXY B.H.N. Ltd., a company aiming to revolutionize acute respiratory care, has announced the appointment of Dr. Adi Rizansky Nir, PhD to the position of Chief Medical Officer.

Eli Lilly and Company will attend the Goldman Sachs 44th Annual Global Healthcare Conference, June 12-13, 2023.

THINK Surgical, Inc., an innovator in the field of orthopedic surgical robots, today announced that its TMINI™ Miniature Robotic System has received 510(k) clearance from the U.S. Food and Drug Administration (FDA).

Genixus, a pharmaceutical company focused on transforming acute and critical care medicines, is pleased to announce the execution of a contract with the 340B Prime Vendor Program, managed by Apexus LLC., for KinetiX Propofol 1% ready-to-administer (RTA) syringes, designed to simplify workflow and support effective care delivery.

Medigene AG, an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, will participate at the BIO International Convention, taking place June 5-8, 2023 in Boston, MA.

According to The Insight Partners market research study titled ‘Nuclear Medicine/Radiopharmaceuticals Market to 2027 – Global Analysis and Forecasts by Applications and End User’.

According to our new research study on “Pharmaceutical Intermediate Market Forecast to 2028 – COVID-19 Impact and Global Analysis – by Type, Applications, and Distribution Channel,”

According to our new market research study on “Cancer Vaccines Market to 2027 – Global Analysis and Forecast by Technology, Type, Indication, and End User,” the market is expected to reach US$ 15,845.59 million by 2027 from US$ 4,568.82 million in 2019

Genprex, Inc. today announced that it has completed the Phase 1 portion of the Acclaim-1 Phase 1/2 clinical trial of REQORSA® in combination with Tagrisso® (osimertinib) to treat late-stage non-small cell lung cancer (NSCLC), and the Safety Review Committee (SRC) has approved continuation to the Phase 2 expansion portion of the trial.

Palatin Technologies, Inc. today announced the presentation of the poster “MC1R Agonist PL8177 Protects Against Podocyte Loss in a Streptozotocin-Induced Rat Model of Diabetic Nephropathy” at the International Podocyte Conference May 24-26, 2023 in Philadelphia, PA.